CYP17A1: A biochemistry, chemistry, and clinical review

Current Topics in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1364-1384

  Porubek, David ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Abiraterone; Androgen; Androstenedione; CYP17A1; Cytochrome P 450; Prostate cancer; Testosterone

Indexed keywords

1 (6,7 DIMETHOXY 2 NAPHTHYL) 1 (1H 1 (6,7 DIMETHOXY 2 NAPHTHYL) 1 (1H IMIDAZOL 4 YL) 2 METHYLPROPAN 1 OL; 17 (3 PYRIDYL)ANDROSTA 5,16 DIEN 3 ONE; 17 (5? ISOXAZOLYL)ANDROSTA 4,16 DIEN 3 ONE; 17 AZOLYL STEROID; 2 (1H IMIDAZOL 4 YL METHYL) 9H CARBAZOLE; 2 (1H IMIDAZOL 4 YLMETHYL) 9H CARBAZOLE; 21 HYDROXYIMINO PREGNA 5,17(20) DIEN 3 OL; 22 HYDROXIMINO 23,24 BISNOR 4 CHOLEN 3 ONE; 3 BETA HYDROXY 17 (1H 1,2,3 TRIAZOL 1 YL) ANDROSTA 5,16 DIENE; 3 BETA HYDROXY 17 (1H BENZIMIDAZOLE 1 YL)ANDROSTA 5,16 DIENE; 3 BETA HYDROXY 17 (1H IMIDAZOL 1 YL)ANDROSTA 5,16 DIENE; 4 PREGNENE 3 ONE 20 BETA CARBOXALDEHYDE; 6 METHYLENEPROGESTERONE; ABIRATERONE; ABIRATERONE ACETATE; BENZOTHIOPHENE DERIVATIVE; CB 7627; CYTOCHROME P450 17; CYTOCHROME P450 17 A1; ENZYME INHIBITOR; GALETERONE; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; MEVINOLIN; ORTERONEL; OXIME DERIVATIVE; PLACEBO; PREDNISONE; PROGESTERONE DERIVATIVE; STEROID; TX 977; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN SYNTHESIS; CASTRATION RESISTANT PROSTATE CANCER; CATALYSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; EDEMA; ENZYME CHEMISTRY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HYDROPHOBICITY; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATION; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURE ANALYSIS; SURVIVAL;

ANIMALS; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR CONFORMATION; PREGNENOLONE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84881344360     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313120002     Document Type: Review

References (136)

1. Mansuy, D. The great diversity of reactions catalyzed by cytochromes P450, Comp. Biochem. Physiol., 1998, 121(1-3): 5-14.
2. Guengerich, F. P. Uncommon P450-catalyzed reactions. Curr Drug Metab., 2001, 2(2): 93-115.
3. Miller, W. L.; Auchus, R. J.; Geller, D. H. The regulation of 17, 20 lyase activity. Steroids, 1997, 62(1): 133-142.
4. Rosenfield, R. L.; Barnes, R. B.; Carc, J. F.; Lucky, A. W.; Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertility and Sterility, 1990, 53(5): 785-791.
5. Namata, H.; Takayanagi, R.; Yanase, T; Ikyama, S.; Okabe, T. Abnormalities of sex differentiation. Hormone Research, 1996, 46 Suppl 1: 15-19.
6. Anchus, R. J.; The genetics, pathophysiology and management of human deficiencies of P450c17. Endocrinol Metab Clinics North Am., 2001, 30(1): 101-119.
7. Lunn, R. M.; Bell, D. M.; Mohler, JL.; Taylor, J. A. Prostate cancer risk and polymorphism in 17-hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 1999, 20 (9): 1727-1731.
8. Sewer, M. B.; Jagarlapudi, S. Complex assembly on the human CYP17 promoter. Mol Cell Endocrinol., 2009, 300(1-2): 109-114.
9. Auchus, R. J. The backdoor pathway to dihydrotestosterone. Trends EndocrinolMetab., 2004, 15(9): 432-438.
10. Wilson, J. D.; Leihy, M. W.; Shaw, G.; Renfree, M. B. Androgen physiology: unsolved problems at the millennium. Mol Cell Endocrinol., 2002, 198(1-2): 1-5.
11. Mohler, J. L.; Titus, M. A.; Wilson, E. M. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res., 2011, 17(18): 5844-5849.
12. Kamrath, C.; Hochberg, Z.; Hartmann M. F.; Remer, T.; Wudy, S. A. Increased Activation of the Alternative "Backdoor" Pathway in Patients with 21-Hydroxylase Deficiency: Evidence from Urinary Steroid Hormone Analysis. J Clin. Endocrinol. Metab., 2012, 97(3) E367-E375.
13. Fan, D. F.; Oshima, H.; Troen, B. R.; Troen, P. Studies of the human testis. IV. Testicular 20 alpha-hydroxysteroid dehydrogenase and steroid 17 alpha-hydroxylase. BiochimBiophysActa., 1974, 360(1): 88-99.
14. Abul-Hajj, Y. J.; Iverson.; Kiang, D. T. Metabolism of pregnenolone by human breast cancer. Evidence for 17 alphahydroxylase and 17, 20-lyase. Steroids, 1979(7): 817-827.
15. Naganuma, H.; Sasano, N. Steroid 21-hydroxylase and 17 alphahydroxylase in microsomal fraction of functioning adrenocortical tumors. Tohoku J Exp Med., 1989(3): 253-262.
16. Stanbrough, M.; Bubley, G. J.; Ross, K.; Golub, T. R.; Rubin, M. A.; Penning, T. M.; Febbo, P. G.; Balk, S. P. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res., 2006, 66, 2815-2825.
17. Kühn-Velten, W. N.; Bunse, T.; Förster, M. E. Enzyme kinetic and inhibition analyses of cytochrome P450XVII, a protein with a bifunctional catalytic site. Quantification of effective substrate concentrations at the active site and their significance for intrinsic control of the hydroxylase/lyase reaction sequence. J. Biol Chem., 1991, 266 (10): 6291-6301.
18. Kitamura, M.; Buczko, E.; Dufau, M. L. Dissociation of hydroxylase and lyase activities by site-directed mutagenesis of the rat P45017 alpha. Mol Endocrinol., 1991, 5(10): 1373-1380.
19. Lorence, M. C.; Trant, J. M.; Clark, B. J.; Khyatt, B; Mason, J. I.; Estabrook, R. W.; Waterman, M. R. Construction and expression of human/bovine P45017 alpha chimeric proteins: evidence for distinct tertiary structures in the same P450 from two different species. Biochemistry, 1990, 29(42): 9819-9824.
20. Hosaka, M.; Oshima, H.; Troen, P. Studies of the human testis. XIV. Properties of C17-C20 lyase. ActaEndocrinol(Copenh)., 1980, 94(3), 389-396.
21. Swart, P.; Swart, A. C.; Waterman, M. R.; Estabrook, R. W.; Mason, J. I. Progesterone 16 alpha-hydroxylase activity is catalyzed by human cytochrome P450 17 alpha-hydroxylase. J. Clin. Endocrinol. Metab., 1993, 77(1), 98-102.
22. Nakajin, S; Takahashi, M.; Shinoda, M.; Hall, P. F. Cytochrome b5 promotes the synthesis of delta 16-C19 steroids by homogeneous cytochrome P-450 C21 side-chain cleavage from pig testis. Biochem. Biophys. Res. Commun., 1985, 132(2), 708-713.
23. Burstein, S.; Middleditch, B. S.; Gut, M. Mass spectrometric study of the enzymatic conversion of cholesterol to (22R)-22-hydroxycholesterol, (20R, 22R)-20, 22-dihydroxycholesterol, and pregnenolone, and of (22R)-22-hydroxycholesterol to the lgycol and pregnenolone in bovine adrenocortical preparations. Mode of oxygen incorporation. J. Biol. Chem., 1975, 250(23), 9028-9037.
24. Larroque, C.; Lange, R.; Maurin, L.; Bienvenue, A.; van Lier, J. E. On the nature of the cytochrome P450scc "ultimate oxidant": characterization of a productive radical intermediate. Arch BiochemBiophys., 1990, 282(1), 198-201.
25. Akhtar, M.; Calder, M. R.; Corina, D. L.; Wright, J. N. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem J., 1982, 201(3), 569-580.
26. Beusen, D. D.; Carrell, H. L.; Covey, D. F. Metabolism of 19-methyl-substituted steroids by human placental aromatase. Biochemistry, 1987, 26(24), 7833-7841.
27. Cole, P. A.; Robinson, C. H. Conversion of 19-oxo[2 beta-2H]androgens into oestrogens by human placental aromatase. An unexpected stereochemical outcome. Biochem J., 1990, 268(3), 553-561.
28. Korzekwa, K. R.; Trager, W. F.; Smith, S. J.; Osawa, Y.; Gillette, J. R. Theoretical studies on the mechanism of conversion of androgens to estrogens by aromatase. Biochemistry, 1991, 30(25), 6155-6162.
29. Corina, D. L.; Miller, S. L.; Wright, J. N.; Akhtar, M. The mechanism of cytochrome P-450 dependent C-C bond cleavage: studies on 17α-hydroxylase-17, 20-lyase. J. Chem. Soc., Chem. Commun., 1991, 782-783.
30. Miller, S. L.; Wright, J. N.; Corina, D. L.; Akhtar, M. Mechanistic studies on pregnene side-chain cleavage enzyme (17α-hydroxylase-17, 20-lyase) using 18O. J. Chem. Soc., Chem. Commun., 1991, 157-159.
31. Mak, A. Y.; Swinney, D. C. 17-O-Acetyltestosterone formation from progesterone in microsomes from pig testes: evidence for the Baeyer-Villiger rearrangement in androgen formation catalyzed by CYP17. J. Am. Chem. Soc., 1992, 114(21), 8309-8310.
32. Tagashira, H.; Kominami, S.; Takemori, S. Kinetic studies of cytochrome P-45017 alpha, lyase dependent and rostenedione formation from progesterone. Biochemistry, 1995, 34(34), 10939-10945.
33. Akhtar, M.; Wright, J. N.; Lee-Robichaud, P. A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17, 20-lyase (CYP17). J SteroidBiochem Mol Bio., 2011, 125(1-2), 2-12.
34. Porter, T. D. The roles of cytochrome b5 in cytochrome P450 reactions. J. Biochem. Mol. Toxicol., 2002, 16(6), 311-316.
35. Akhtar, M. K.; Kelly, S. L.; Kaderbhai, M. A. Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J Endocrinol., 2005, 187(2), 267-274.
36. Lin, D.; Black, S. M.; Nagahama, Y.; Miller, W. L. Steroid 17 alpha-hydroxylase and 17, 20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology, 1993, 132(6), 2498-2506.
37. Pandey, A. V.; Miller, W. L. Regulation of 17, 20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J Biol Chem., 2005, 280(14), 13265-13271.
38. Wang, Y. H.; Tee, M. K.; Miller, W. L. Human cytochrome p450c17: single step purification and phosphorylation of serine 258 by protein kinase a. Endocrinology, 2010, 151(4), 1677-1684.
39. Laughton, C. A.; Neidle, S.; Zvelebil, M. J.; Sternberg, M. J. A molecular model for the enzyme cytochrome P450(17 alpha), a major target for the chemotherapy of prostatic cancer. Biochem. Biophys. Res. Commun., 1990, 171(3), 1160-1167.
40. Korzekwa, K. R.; Trager, W. F.; Mancewicz, J.; Osawa, Y. Studies on the mechanism of aromatase and other cytochrome P450 mediated deformylation reactions. J. Steroid Biochem. Mol Biol., 1993, 44(4-6), 367-373.
41. Koppenol, W. H. Oxygenactivation by cytochrome p450: a thermodynamic analysis. J Am Chem Soc., 2007, 129(31), 9686-9690.
42. Guengerich, F. P.; Sohl, C. D.; Chowdhury, G. Multi-step oxidations catalyzed by cytochrome P450 enzymes: Processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms. Arch BiochemBiophys., 2011, 507(1), 126-134.
43. Sharma, P. K.; De Visser, S. P.; Ogliaro, F.; Shaik, S. Is the ruthenium analogue of compound I of cytochrome p450 an efficient oxidant? A theoretical investigation of the methane hydroxylation reaction. J Am Chem Soc., 2003, 125(8), 2291-2300.
44. Miller, W. L.; Huang, N.; Pandey, A. V.; Flück, C. E.; Agrawal, V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci., 2005, 1061, 100-108.
45. Sandee, D.; Miller, W. L. High-yield expression of a catalytically active membrane-bound protein: human P450 oxidoreductase. Endocrinology, 2011, 152(7), 2904-2908.
46. Shumiantseva, V. V.; Bulko, T. V.; Misharin, A. I.; Archakov, A. A. Screening of potential substrates or inhibitors of cytochrome P450 17A1 (CYP17A1) by electrochemical methods. Biomed Khim., 2011, 57(4), 402-409.
47. Soucy, P.; Luu-The, V. Assessment of the ability of type 2 cytochrome b5 to modulate 17, 20-lyase activity of human P450c17. J Steroid Biochem Mol Biol., 2002, 80(1), 71-75.
48. Billen, M. J.; Squires, E. J. The role of porcine cytochromeb5A and cytochrome b5B in the regulation of cytochrome P45017A1 activities. J Steroid Biochem Mol Biol., 2009, 113(1-2), 98-104.
49. Miller, W. L. The syndrome of 17, 20 lyase deficiency. J. Clin. Endocrinol. Metab., 2012, 97(1), 59-67.
50. Gupta, M. K.; Geller, D. H.; Auchus, R. J. Pitfalls in characterizing P450c17 mutations associated with isolated 17, 20-lyase deficiency. J. Clin. Endocrinol. Metab., 2001, 86(9), 4416-4423.
51. Van Den Akker, E. L.; Koper, J. W.; Boehmer, A. L.; Themmen, A. P.; Verhoef-Post, M.; Timmerman, M. A,; Otten, B. J.; Drop, S. L.; De Jong, F. H. Differential inhibition of 17alpha-hydroxylase and 17, 20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab., 2002, 87(12), 5714-5721.
52. Patocs, A.; Liko, I.; Varga, I.; Gergics, P.; Boros, A.; Futo, L.; Kun, I.; Bertalan, R.; Toth, S.; Pazmany, T.; Toth, M.; Szücs, N.; Horanyi, J.; Glaz, E.; Racz, K. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17, 20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling. J Steroid Biochem Mol Biol., 2005, 97(3), 257-265.
53. Park, J. M.; Lee, E. J.; Ramakrishna, S.; Cha, D. H.; Baek, K. H. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med., 2008, 22(2), 249-254.
54. Rosa, S.; Steigert, M.; Lang-Muritano, M.; l'Allemand, D.; Schoenle, E. J.; Biason-Lauber, A. Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17, 20-lyase deficiency. Horm Res Paediatr., 2010, 73(3), 198-204.
55. Katsumata, N.; Ogawa, E.; Fujiwara, I.; Fujikura, K. Novel CYP17A1 mutation in a Japanese patient with combined 17alphahydroxylase/17, 20-lyase deficiency. Metabolism, 2010, 59(2), 275-288.
56. Wang W, Fu JF, Gong FQ, Zhu WH, Shen Z. Rare hypertension as a result of 17alpha-hydroxylase deficiency. J PediatrEndocrinol-Metab., 2011, 24(5-6), 333-337.
57. Bee, Y. M.; Manju, C.; Papari-Zareei, M.; Auchus, R. J. Phenotypic variation in a Chinese family with 46, XY and 46, XX 17α-hydroxylase deficiency. GynecolEndocrinol., 2012, 28(4), 322-325.
58. Hwang, D. Y.; Hung, C. C.; Riepe, F. G.; Auchus, R. J.; Kulle, A. E.; Holterhus, P. M.; Chao, M. C.; Kuo, M. C.; Hwang, S. J.; Chen, H. C. CYP17A1 intron mutation causing cryptic splicing in 17α-hydroxylase deficiency. PLoS One, 2011, 6(9), e25492.
59. Flück, C. E.; Nicolo, C.; Pandey, A. V. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. FundamClinPharmacol., 2007(4), 399-410.
60. Pandey, A. V.; Kempná, P.; Hofer, G.; Mullis, P. E.; Flück, C. E. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol., 2007, 21(10), 2579-2595.
61. Flück, C. E.; Mallet, D.; Hofer, G.; Samara-Boustani, D.; Leger, J.; Polak, M.; Morel, Y,; Pandey, A. V. Deletion of P399-E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. BiochemBiophys Res Commun., 2011, 412(4), 572-577.
62. Kok, R. C.; Timmerman, M. A.; Wolffenbuttel, K. P.; Drop, S. L.; de Jong, F. H.; Isolated 17, 20-lyase deficiency due to the cytochrome b5 mutation W27X. J. Clin. Endocrinol. Metab., 2010, 95(3), 994-999.
63. Idkowiak, J.; Randell, T.; Dhir, V.; Patel, P.; Shackleton, C. H.; Taylor, N. F.; Krone, N.; Arlt, W. A Missense Mutation in the Human Cytochrome b5 Gene causes 46, XY Disorder of Sex Development due to True Isolated 17, 20 Lyase Deficiency. J. Clin. Endocrinol. Metab., 2011, 97(3), E465-E475.
64. Shikita, M.; Ogiso, T.; Tamaoki, B. I. Effect of inhibitors on testicular microsomal steroid 17-alpha-hydroxylase and 17-alphahydroxypregnene C17-C20 lyase. Biochem. Biophys. Acta., 1965, 105(3), 516-522.
65. Nakajin, S.; Hall, P. F.; Onoda M. Testicular microsomal cytochrome P-450 for C21 steroid side chain cleavage. Spectral and binding studies. J Biol Chem., 1981, 256(12), 6134-6139.
66. Nakajin, S.; Kobune, S.; Shinoda, M. Carbon monoxide inhibition of 21-hydroxylase and 17 alpha-hydroxylase activities in porcine adrenal microsomes. YakugakuZasshi, 1983, 103(8), 895-898.
67. Nakajin, S.; Hall, P. F. Side-chain cleavage of C21 steroids by testicular microsomal cytochrome P-450 (17 alphahydroxylase/lyase): involvement of heme. J SteroidBiochem., 1983, 19(3), 1345-1348.
68. Kan, P. B.; Hirst, M. A.; Feldman, D. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J SteroidBiochem., 1985, 23(6A), 1023-1029.
69. Hornsby, P. J.; Aldern, K. A.; Harris, S. E. Methylcholanthrene: a possible pseudosubstrate for adrenocortical 17 alpha-hydroxylase and aryl hydrocarbon hydroxylase. Biochem. Pharmacol., 1986, 35(19), 3209-3219.
70. Mebus, C. A.; Reddy, V.; Piper, W. N. Depression of rat testicular 17-hydroxylase and 17, 20-lyase after administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). Biochem. Pharmacol., 1987, 36(5), 727-731.
71. Ayub, M.; Levell, M. J. Inhibition of rat testicular 17 alphahydroxylase and 17, 20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J. Steroid Biochem., 1987, 28(1): 43-47.
72. Ayub, M.; Levell, M. J. Inhibition of testicular 17 alphahydroxylase and 17, 20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroidoxidoreductase by ketoconazole and other imidazole drugs. J SteroidBiochem., 1987, 28(5): 521-531.
73. Engelhardt, H.; Gore-Langton, R. E.; Armstrong, D. T. Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of the 17 alpha-hydroxylase: C-17, 20-lyase complex. Endocrinology. 1998, 124(5): 2297-2304.
74. Nakajin, S.; Takahashi, K.; Shinoda, M. Inhibitory effect and interaction of stanozolol with pig testicular cytochrome P-450 (17 alpha-hydroxylase/C17, 20-lyase). Chem Pharm Bull (Tokyo), 1989, 37(7): 1855-1858.
75. Angelastro, M.; Laughlin, M. E.; Schatzman, G. L.; Bey, P.; Blohm, T. R. 17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase). BiochemBiophys Res Commun., 1989, 162(3): 1571-1577.
76. LaCagnin, L. B.; Levitt, M.; Bergstrom, J. M.; Colby, H. D. Inhibition of adrenocortical, mitochondrial and microsomal monooxygenases by SU-10'603, a steroid 17 alpha-hydroxylase inhibitor. J SteroidBiochem., 1989, 33(4A): 599-604.
77. McCague, R.; Rowlands, M. G.; Barrie, S. E.; Houghton, J. Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J Med Chem., 1990, 33(11): 3050-3055.
78. Li, J.; Li, Y.; Son, C.; Banks, P.; Brodie, A. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alphahydroxylase/C17, 20-lyase and of 5 alpha-reductase. J SteroidBiochem Mol Biol., 1992, 42(3-4): 313-320.
79. Kossor, D. C.; Kominami, S.; Takemori, S.; Colby, H. D. Destruction of testicular cytochrome P-450 by 7 alpha-thiospironolactone is catalyzed by the 17 alpha-hydroxylase. J SteroidBiochem Mol Biol., 1992, 42(3-4): 421-424.
80. Neubauer, B. L.; Best, K. L.; Blohm, T. R.; Gates, C.; Goode, R. L.; Hirsch, K. S.; Laughlin, M. E.; Petrow, V.; Smalstig, E. B.; Stamm, N. B.; Toomey, R. E.; Hoover, D. M. LY207320 (6-methylene-4-pregnene-3, 20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats. Prostate, 1993, 23(3): 181-199.
81. Laughton, C. A.; Neidle, S.; Zvelebil, M. J.; Sternberg, M. J. A molecular model for the enzyme cytochrome P450(17 alpha), a major target for the chemotherapy of prostatic cancer. BiochemBiophys Res Commun., 1990, 171(3): 1160-1167.
82. Ahmed, S. Molecular modelling of known non-steroidal inhibitors of 17 alpha-hydroxylase/17, 20-lyase using antimycotic compounds. Drug Des Discov., 1994, 12(1): 77-88.
83. Barrie, S. E.; Potter, G. A.; Goddard, P. M.; Haynes, B. P.; Dowsett, M.; Jarman, M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J SteroidBiochem Mol Biol., 1994, 50(5-6): 267-273.
84. Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alphahydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem., 1995, 38(13): 2463-2471.
85. Li, J.; Li, Y.; Son, C.; Brodie, A. M. Inhibition of androgen synthesis by 22-hydroximino-23, 24-bisnor-4-cholen-3-one. Prostate, 1995, 26(3): 140-150.
86. Chan, F. C.; Potter, G. A.; Barrie, S. E.; Haynes, B. P.; Rowlands, M. G.; Houghton. J.; Jarman, M. 3-and 4-Pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17, 20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem., 1996, 39(17): 3319-3323.
87. Burkhart, J. P.; Gates, C. A.; Laughlin, M. E.; Resvick, R. J.; Peet, N. P. Inhibition of steroid C17(20) lyase with C-17-heteroaryl steroids. Bioorg Med Chem., 1996, 4(9): 1411-1420.
88. Njar, V. C.; Hector, M.; Hartmann, R. W. 20-amino and 20, 21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase/C17, 20-lyase (P450 17). Bioorg Med Chem., 1996, 4(9): 1447-1453.
89. Burke, D. F.; Laughton, C. A.; Neidle, S. Homology modelling of the enzyme P450 17 alpha-hydroxylase/17, 20-lyase--a target for prostate cancer chemotherapy--from the crystal structure of P450BM-3. Anticancer Drug Des., 1997, 12(2): 113-123.
90. Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Yoden, T.; Okada, M.; Fujikura, T.; Akaza, H.; Shikama, H. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate, 1998, 37(1): 10-18.
91. Njar, V. C.; Kato, K.; Nnane, I. P.; Grigoryev, D. N.; Long, B. J.; Brodie, A. M. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17, 20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem., 1998, 41(6): 902-912.
92. Grigoryev, D. N.; Long, B. J.; Nnane, I. P.; Njar, V. C.; Liu, Y.; Brodie, A. M. Effects of new 17alpha-hydroxylase/C(17, 20)-lyaseinhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer, 1999, 81(4): 622-630.
93. Nnane, I. P.; Njar, V. C.; Liu, Y.; Lu, Q.; Brodie, A. M. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J SteroidBiochem Mol Biol., 1999, 71(3-4): 145-152.
94. Ahmed, S.; Keane, J. Modeling study of some inhibitors of 17, 20-lyase, a component of the enzyme 17 alpha-hydroxylase/17, 20-lyase: a novel approach. Biochem. Biophys Res. Commun., 1998, 253(2): 273-276.
95. Grigoryev, D. N.; Kato, K.; Njar, V. C.; Long, B. J.; Ling, Y. Z.; Wang, X.; Mohler, J.; Brodie, A. M. Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17alpha-hydroxylase-C17, 20-lyase inhibitors. Anal Biochem., 1999, 267(2): 319-330.
96. Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Fujikura, T.; Akaza, H.; Shikama, H. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol., 1999, 79(2): 213-220.
97. Hartmann, R. W.; Hector, M.; Haidar, S.; Ehmer, P. B.; Reichert, W.; Jose, J. Synthesis and evaluation of novel steroidal oximeinhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2. J Med Chem., 2000, 43(22): 4266-4277.
98. Hartmann, R. W.; Hector, M.; Wachall, B. G.; Palusczak, A.; Palzer, M.; Huch, V.; Veith, M. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alphahydroxylase/C17-20-lyase (P450 17). J Med Chem., 2000, 43(23): 4437-4445.
99. Long, B. J.; Grigoryev, D. N.; Nnane, I. P.; Liu, Y.; Ling, Y. Z.; Brodie, A. M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res., 2000, 60(23): 6630-6640.
100. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alphahydroxylase-C(17, 20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli. J SteroidBiochem Mol Biol., 2000, 75(1): 57-63.
101. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme. J Enzyme Inhib Med Chem., 2004, 19(1): 17-32.
102. Nnane, I. P.; Njar, V. C.; Brodie, A. A. Pharmacokinetic profile of 3beta-hydroxy-17-(1H-1, 2, 3-triazol-1-yl)androsta-5, 16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice. J. Steroid Biochem. Mol. Biol., 2001, 78(3): 241-246.
103. Handratta, V. D.; Jelovac, D.; Long, B. J.; Kataria, R.; Nnane, I. P.; Njar, V. C.; Brodie, A. M. Potent CYP17inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J. Steroid Biochem. Mol. Biol., 2004, 92(3): 155-165.
104. Duc, I.; Bonnet, P.; Duranti, V.; Cardinali, S.; Rivière, A.; De Giovanni, A.; Shields-Botella, J.; Barcelo, G.; Adje, N.; Carniato, D.; Lafay, J.; Pascal, J. C.; Delansorne, R. In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alphahydroxylase/C17, 20-lyase. J SteroidBiochem Mol Biol., 2003, 84(5): 537-542.
105. Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol. Biol., 2003, 84(5): 555-562.
106. Clement, O. O.; Freeman, C. M.; Hartmann, R. W.; Handratta, V. D.; Vasaitis, T. S.; Brodie, A. M.; Njar, V. C. Three dimensional pharmacophore modeling of human CYP17inhibitors. Potential agents for prostate cancer therapy. J Med Chem., 2003, 46(12): 2345-2351.
107. PenovGasi, K. M.; Miljković, D. A.; Medić Mijacević, L. D.; Djurendić, E. A.; Stojanović, S. Z.; Sakac, M. N.; Djurendić, M. D.; Stanković, S. M.; Lazar, D.; Andrić, S.; Kovacević, R. Synthesis, X-ray crystal structures and biological activity of 16-amino-17-substituted-D-homo steroid derivatives. Steroids, 2003, 68(7-8): 667-676.
108. Matsunaga, N.; Kaku, T.; Itoh, F.; Tanaka, T.; Hara, T.; Miki, H.; Iwasaki, M.; Aono, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. C17, 20-lyase inhibitors I. Structure-based de novo design and SAR study of C17, 20-lyase inhibitors. Bioorg Med Chem., 2004, 12(9): 2251-2273.
109. Matsunaga, N.; Kaku, T.; Ojida, A.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. C(17, 20)-lyaseinhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17, 20)-lyaseinhibitors. Bioorg Med Chem., 2004, 12(16): 4313-4336.
110. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D. Jr,; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. Novel C-17-heteroaryl steroidal CYP17inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem., 2005, 48(8): 2972-2984.
111. Vasaitis, T.; Belosay, A.; Schayowitz, A.; Khandelwal, A.; Chopra, P.; Gediya, L. K.; Guo, Z.; Fang, H. B.; Njar, V. C.; Brodie, A. M. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17, 20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5, 16-diene in prostate cancer. Mol Cancer Ther., 2008(8): 2348-2357.
112. Owen, C. P.; Dhanani, S.; Patel, C. H.; Shahid, I.; Ahmed, S. Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17, 20-lyase (P450(17alpha). Bioorg. Med. Chem. Lett., 2006, 16(15): 4011-4015.
113. Moreira, V. M.; Vasaitis, T. S.; Njar, V. C.; Salvador, J. A. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17inhibitors. Steroids, 2007, 72(14): 939-948.
114. Shahid, I.; Patel, C. H.; Dhanani, S.; Owen, C. P.; Ahmed, S. Synthesis, biochemical evaluation of a range of potent 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-Hydroxylase/17, 20-Lyase (P45017alpha). J SteroidBiochem Mol Biol., 2008, 110(1-2): 18-29.
115. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-BazurcoMendieta, M. A.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17, 20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. Bioorg Med Chem., 2008, 16(4): 1992-2010.
116. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17, 20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. Bioorg. Med. Chem., 2008, 16(16): 7715-7727.
117. Pinto-BazurcoMendieta, M. A.; Negri, M.; Jagusch, C.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17inhibitors for the treatment of prostate cancer. J Med Chem., 2008, 51(16): 5009-5018.
118. Ahmed, S.; Shahid, I.; Dhanani, S.; Owen, C. P. Synthesis and biochemical evaluation of a range of sulfonated derivatives of 4-hydroxybenzyl imidazole as highly potent inhibitors of rat testicular 17alpha-hydroxylase/17, 20-lyase (P-450(17alpha). Bioorg Med ChemLett., 2009, 19(16): 4698-4701.
119. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med., 2000, 6: 703-706.
120. Hu, Q.; Jagusch, C.; Hille, U. E.; Haupenthal, J.; Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. J Med Chem., 2010, 53(15): 5749-5758.
121. Hu, Q.; Negri, M.; Olgen, S.; Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17inhibitors for the treatment of prostate carcinoma. Chem Med Chem., 2010, 5(6): 899-910.
122. Hu, Q.; Yin, L.; Jagusch, C.; Hille, U. E.; Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17inhibitors. J Med Chem., 2010, 53(13): 5049-5053.
123. Haider, S. M.; Patel, J. S.; Poojari, C. S.; Neidle, S. Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy. J Mol Biol., 2010, 400(5): 1078-1098.
124. Bruno, R. D.; Vasaitis, T. S.; Gediya, L. K.; Purushottamachar, P.; Godbole, A. M.; Ates-Alagoz, Z.; Brodie, A. M.; Njar, V. C. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 2011, 76(12): 1268-79.
125. Kaku, T.; Hitaka, T.; Ojida, A.; Matsunaga, N.; Adachi, M.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Okuda, T.; Asahi, S.; Furuya, S.; Tasaka, A. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17, 20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem., 2011, 19(21): 6383-6399.
126. Kaku, T.; Tsujimoto, S.; Matsunaga, N.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. 17, 20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17, 20-lyase inhibitors. Bioorg Med Chem., 2011, 19(7): 2428-2442.
127. Kaku, T.; Matsunaga, N.; Ojida, A.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. 17, 20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17, 20-lyase inhibitors. Bioorg Med Chem., 2011, 19(5): 1751-1770.
128. DeVore, N. M.; Scott, E. E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature, 2012, 482(7383): 116-119.
129. Yap, T. A.; Carden, C. P.; Attard, G.; de Bono, J. S. Targeting CYP17: established and novel approaches in prostate cancer. Curr. Opin. Pharmacol., 2008, 8(4): 449-457.
130. Jarman, M.; Barrie, S. E.; Llera, J. M. The 16, 17-double bond is needed for irreversible inhibition of human cytochrome P450 17α by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3β-ol) and related steroidal inhibitors, J. Med. Chem., 1998, 41(27): 5375-5381.
131. Zytiga package insert. www. accessdata. fda. gov/drugsatfda_docs/label/2011/202379lbl. pdf (Accessed February 1, 2013).
132. Yamaoka, M.; Hara, T.; Hitaka, T.; Kaku, T.; Takeuchi, T.; Takahashi, J.; Asahi, S.; Miki, H.; Tasaka, A.; Kusaka, M. Orteronel (TAK-700), a novel non-steroidal 17, 20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol., 2012, 129(3-5): 115-128.
133. Taplin, M. E.; Chu, F.; Morrison, J. P.; Pili, R.; Rettig, M. B.; Stephenson, J.; Vogelzang, N. J.; Montgomery, R. B. Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC). Abstract CT-07. AACR 2012 (March 31-April 4, 2012).
134. Sharifi, N. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med., 2012, 60(2): 504-507.
135. Cai, C.; Chen, S.; Ng, P.; Bubley, G. J.; Nelson, P. S.; Mostaghel, E. A.; Marck, B.; Matsumoto, A. M.; Simon, N. I.; Wang, H.; Chen, S.; Balk, S. P. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res., 2011, 71(20): 6503-6513.
136. Soifer, H. S.; Souleimanian, N.; Wu, S.; Voskresenskiy, A. M.; KisaayakCollak, F.; Cinar, B.; Stein, C. A. Direct Regulation of Androgen Receptor Activity by Potent CYP17Inhibitors in Prostate Cancer Cells. J Biol Chem., 2012, 287(6): 3777-3787.